TanoMed
Immunotherapy Solutions for GI Cancers
Company Overview
Snapshot
Founded in August 2020 by Helena Florindo and Ronit Satchi-Fainaro, TanoMed operates with 1–10 employees. The company is currently in a Pre-Funding stage.
Business overview
TanoMed specializes in developing precision immuno-oncology therapies for gastrointestinal cancers. The company's core technology involves immune cell-targeted nanodelivery solutions designed to enhance therapeutic efficacy by stimulating tumor destruction through T- and B-cell priming. TanoMed's platform utilizes a novel dendritic cell-targeted nano-immunomodulator that combines antigen-carrying capacity with in vivo targeting and modulation of dendritic cell function, aiming to expand the host's antitumor specific T-effector phenotype and improve long-term tumor recognition. TanoMed operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development.
Log in to access full profile ›Company Intelligence Q&A
- What is TanoMed's primary focus?
- TanoMed is focused on developing immunotherapy solutions specifically for gastrointestinal (GI) cancers, utilizing advanced nanodelivery techniques.
- When was TanoMed founded?
- TanoMed was founded in August 2020.
- Who are the founders of TanoMed?
- TanoMed was co-founded by Helena Florindo and Ronit Satchi-Fainaro.
- What is TanoMed's current operational status?
- TanoMed is currently non-active, having ceased operations in February 2022.
- What technology does TanoMed employ?
- TanoMed employs a novel dendritic cell-targeted nano-immunomodulator platform designed to combine antigen-carrying capacity with in vivo targeting and modulation of dendritic cell function, aiming to improve therapeutic efficacy in oncology.